ADC Therapeutics SA ADCT

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived NYSE

ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates ("ADCs"), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC. ZYNLONTA received accelerated approval from the U.S. Food and Drug Administration ("FDA") and conditional approval from the European Commission, China National Medical Products Administration ("NMPA") and Health Canada for the treatment of relapsed or refractory DLBCL after two or more lines of systemic therapy. We are pursuing expansion of ZYNLONTA internationally, and into earlier lines of diffuse large B-cell lymphoma ("DLBCL") through our LOTIS-5 confirmatory Phase 3 clinical trial (rituximab combination) and LOTIS-7 Phase 1b clinical trial (bispecific combination) as well as into indolent lymphomas, including marginal zone lymphoma ("MZL") and follicular lymphoma ("FL"), through investigator-initiated trials ("IITs") at leading institutions.

Last close 1.44 2026-10-23
Market cap $183.8M 2026-06-30 share count
52-week range 0.78 - 4.98

Valuation FY2025 figures against the last close

P/S2.3x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.12

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • U.S.
  • Emea
Revenue by geography, 2 categories over 2 years. The same figures are in the table below. FY2025 U.S., FY2025: 73.6M (90.4%) 90% U.S. Emea, FY2025: 7.8M (9.6%) 10% Emea FY2024 U.S., FY2024: 69.3M (97.8%) 98% Emea, FY2024: 1.6M (2.2%)
Region FY2025FY2024
U.S. $73.6M $69.3M
Emea $7.8M $1.6M

As the company reported it, from the “Revenue - Schedule of Disaggregation of Revenues (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue $81.4M$70.8M$69.6M$74.9M—————
Cost of revenue $5.8M$5.9M$2.5M$3.3M—————
Gross profit $75.6M$64.9M$67.0M$71.6M—————
R&D $104.0M$109.6M$127.1M$186.5M—————
SG&A $36.6M$41.9M$48.4M$74.4M—————
Total operating expenses $202.9M$201.5M$235.5M$333.3M—————
Operating income -$121.5M-$130.7M-$166.0M-$123.3M-$261.7M-$219.3M-$119.4M-$125.9M—
Interest expense $51.6M$50.2M$46.3M$36.7M—————
Pre-tax income -$141.6M-$156.1M-$195.4M-$146.8M—————
Income tax $1.0M$166.0K$39.1M$227.0K—————
Net income -$142.6M-$157.8M-$240.1M-$157.1M-$230.0M-$246.3M-$116.5M-$123.1M—
EPS, basic -1.12-1.62-2.94-2.01—————
EPS, diluted -1.12-1.62-2.94-2.01—————
Shares, diluted (wtd. avg.) 127.1M97.2M81.7M78.2M—————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents $261.3M$250.9M$278.6M$326.4M$466.5M————
Inventory $4.2M$2.3M$16.2M$12.1M—————
Total current assets $306.3M$291.3M$336.3M$435.0M—————
Property, plant and equipment $0$5.1M$5.6M$3.4M—————
Total assets $323.1M$322.0M$354.8M$490.9M$618.0M$513.7M$137.7M——
Accounts payable $9.2M$18.0M$15.6M$12.4M—————
Short-term debt $3.0M$0———————
Total current liabilities $70.2M$80.5M$67.7M$81.9M—————
Total liabilities $509.0M$524.6M$503.0M$411.4M—————
Retained earnings -$1.64B-$1.49B-$1.34B-$1.10B—————
Total equity -$185.8M-$202.6M-$148.2M$79.5M$154.0M$335.5M$111.2M$126.2M$249.2M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating cash flow -$141.2M-$123.8M-$118.7M-$138.3M—————
Depreciation and amortisation $705.0K$1.3M$1.2M$1.1M—————
Stock-based compensation $6.9M$6.6M$13.5M$49.3M—————
Capital expenditure $264.0K$867.0K$3.2M$687.0K—————
Investing cash flow $395.0K-$867.0K-$3.2M-$687.0K—————
Financing cash flow $150.9M$97.1M$73.9M-$897.0K—————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-015491.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -300M -200M -100M 0 100M Net income, FY2018: -123.1M Net income, FY2019: -116.5M Net income, FY2020: -246.3M Net income, FY2021: -230M Revenue, FY2022: 74.9M Gross profit, FY2022: 71.6M Net income, FY2022: -157.1M Revenue, FY2023: 69.6M Gross profit, FY2023: 67M Net income, FY2023: -240.1M Revenue, FY2024: 70.8M Gross profit, FY2024: 64.9M Net income, FY2024: -157.8M Revenue, FY2025: 81.4M Gross profit, FY2025: 75.6M Net income, FY2025: -142.6M FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — — — — — $74.9M $69.6M $70.8M $81.4M
Gross profit — — — — — $71.6M $67.0M $64.9M $75.6M
Net income — -$123.1M -$116.5M -$246.3M -$230.0M -$157.1M -$240.1M -$157.8M -$142.6M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Item 7.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Regulation FD disclosure Item 7.01
  • Other event Item 8.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%